Akebia Therapeutics
245 First Street
Suite 1100
Cambridge
Massachusetts
02142
United States
Tel: 617-871-2098
Fax: 617-871-2099
Website: http://www.akebia.com/
165 articles with Akebia Therapeutics
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on September 28, 2018
10/2/2018
Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 32,750 shares of Akebia’s common stock on September 28, 2018, as inducements material to each such employee’s entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
-
Akebia Therapeutics to Participate in Upcoming October 2018 Investor Conferences
9/25/2018
Akebia Therapeutics, Inc. today announced that it will participate in the following investor conferences:
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on August 31, 2018
9/4/2018
Akebia Therapeutics, Inc. granted a newly-hired employee options to purchase an aggregate of 1,250 shares of Akebia’s common stock on August 31, 2018
-
Akebia Therapeutics Appoints Cynthia Smith to Its Board of Directors
8/28/2018
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the appointment of Cynthia Smith to its Board of Directors.
-
The U.S. Securities and Exchange Commission has leveled charges at a former Sangamo Therapeutics Inc. executive and others for an insider-trading scheme that netted more than $1.5 million in “illegal profits.”
-
Akebia Therapeutics Announces Second Quarter 2018 Financial Results
8/8/2018
Company to Host Conference Call Today at 4:30 p.m. Eastern Time
-
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) on July 31, 2018
8/2/2018
Akebia Therapeutics, Inc. granted eight newly-hired employees options to purchase an aggregate of 37,400 shares of Akebia’s common stock on July 31, 2018, as inducements material to each such employee’s entering into employment with Akebia.
-
Akebia Therapeutics to Host Second Quarter 2018 Investor Update Call and Webcast
8/1/2018
Akebia Therapeutics, Inc. announced it will host a second quarter 2018 investor update conference call and webcast at 4:30 p.m. on Wednesday, August 8, 2018.
-
Pre-Market Research Reports on Biotech Stocks -- Agenus, Aimmune Therapeutics, Akebia Therapeutics, and Alder Biopharma
7/25/2018
On Tuesday, key US indices were mixed as the NASDAQ Composite finished the trading session down 0.01%; the Dow Jones Industrial Average edged 0.79% higher; and the S&P 500 was up 0.48%.
-
Schultz Chan, the former director of biostatistics at Cambridge-based Akebia Therapeutics and Songjiang Wang, a director of statistical programming at Merrimack Pharmaceuticals (MACK) were convicted of insider trading by a federal grand jury in Boston.
-
So far during the first six months of the year, more than $100 billion has been spent on a myriad of acquisitions across the pharma and biotech industries.
-
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on June 29, 2018
7/2/2018
Akebia Therapeutics, Inc. granted six newly-hired employees options to purchase an aggregate of 12,050 shares of Akebia’s common stock on June 29, 2018
-
Akebia Therapeutics and Keryx Biopharmaceuticals to Merge, Creating a Fully Integrated Company Focused on the Development and Commercialization of Therapeutics for Patients with Kidney Disease
6/28/2018
Expects to Capture Significant Operating and Product Portfolio Synergies, Accelerating Revenue Growth and Creating Shareholder Value.
-
Shares of Akebia Therapeutics are up more than 10 percent in premarket trading after the company announced it struck a merger agreement with Keryx Biopharmaceuticals, Inc. to create a company expected to be a leader in the development of renal disease therapies.
-
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) on May 31, 2018
6/4/2018
Akebia Therapeutics, Inc. granted four newly-hired employees options to purchase an aggregate of 21,300 shares of Akebia’s common stock
-
Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) Last April 30, 2018
5/2/2018
Akebia Therapeutics, Inc. granted five newly-hired employees options to purchase an aggregate of 10,450 shares of Akebia’s common stock on April 30, 2018.
-
Akebia Announces $85M Public Offering
3/23/2018
Akebia Therapeutics, a kidney disease company, announced plans to offer and sell about $85 million of its common stock in an underwritten public offering. -
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock
3/23/2018
Akebia announced the pricing of an underwritten public offering of 8,500,000 shares of common stock at a price to the public of $10.50 per share.
-
Akebia Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
3/12/2018
Akebia Therapeutics, Inc. announced financial results for the fourth quarter and full year ended December 31, 2017.
-
Akebia Therapeutics Provides Update on Vadadustat Development Program
2/12/2018
Akebia today provided an update on the global development plan for vadadustat, an oral HIF stabilizer in global Phase 3 development for the treatment of anemia due to chronic kidney disease.